SG11201507506RA - Nanoscale artificial antigen presenting cells - Google Patents
Nanoscale artificial antigen presenting cellsInfo
- Publication number
- SG11201507506RA SG11201507506RA SG11201507506RA SG11201507506RA SG11201507506RA SG 11201507506R A SG11201507506R A SG 11201507506RA SG 11201507506R A SG11201507506R A SG 11201507506RA SG 11201507506R A SG11201507506R A SG 11201507506RA SG 11201507506R A SG11201507506R A SG 11201507506RA
- Authority
- SG
- Singapore
- Prior art keywords
- presenting cells
- antigen presenting
- artificial antigen
- nanoscale artificial
- nanoscale
- Prior art date
Links
- 210000000612 antigen-presenting cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/10—Mineral substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361786135P | 2013-03-14 | 2013-03-14 | |
US201461942797P | 2014-02-21 | 2014-02-21 | |
PCT/US2014/025889 WO2014160132A1 (en) | 2013-03-14 | 2014-03-13 | Nanoscale artificial antigen presenting cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201507506RA true SG11201507506RA (en) | 2015-10-29 |
Family
ID=51625342
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201707377XA SG10201707377XA (en) | 2013-03-14 | 2014-03-13 | Nanoscale artificial antigen presenting cells |
SG11201507506RA SG11201507506RA (en) | 2013-03-14 | 2014-03-13 | Nanoscale artificial antigen presenting cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201707377XA SG10201707377XA (en) | 2013-03-14 | 2014-03-13 | Nanoscale artificial antigen presenting cells |
Country Status (12)
Country | Link |
---|---|
US (2) | US10435668B2 (he) |
EP (1) | EP2970907B1 (he) |
JP (1) | JP6632072B2 (he) |
KR (1) | KR102164405B1 (he) |
CN (1) | CN105431523B (he) |
AU (1) | AU2014244119B2 (he) |
CA (1) | CA2906514C (he) |
ES (1) | ES2782002T3 (he) |
IL (1) | IL241627B (he) |
MX (1) | MX2015012920A (he) |
SG (2) | SG10201707377XA (he) |
WO (1) | WO2014160132A1 (he) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6632072B2 (ja) | 2013-03-14 | 2020-01-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | ナノスケール人工抗原提示細胞 |
EP3995145A1 (en) | 2013-06-24 | 2022-05-11 | NexImmune, Inc. | Compositions and methods for immunotherapy |
KR20210032011A (ko) * | 2014-09-17 | 2021-03-23 | 더 존스 홉킨스 유니버시티 | 항원-특이적 t 세포 식별, 농축, 및/또는 증식을 위한 시약 및 방법 |
EP3970748A1 (en) | 2014-12-24 | 2022-03-23 | NexImmune, Inc. | Nanoparticle compositions and methods for immunotherapy |
US10539564B2 (en) | 2015-07-22 | 2020-01-21 | Roche Sequencing Solutions, Inc. | Identification of antigen epitopes and immune sequences recognizing the antigens |
EP3325646B1 (en) * | 2015-07-22 | 2020-08-19 | F.Hoffmann-La Roche Ag | Identification of antigen epitopes and immune sequences recognizing the antigens |
CA3017615A1 (en) * | 2016-03-16 | 2017-09-21 | Neximmune, Inc. | Production of antigen-specific t-cells |
AU2017283480A1 (en) | 2016-06-13 | 2019-01-24 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
WO2018018017A1 (en) | 2016-07-21 | 2018-01-25 | Berkeley Lights, Inc. | Sorting of t lymphocytes in a microfluidic device |
US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
CN110381989A (zh) * | 2016-12-21 | 2019-10-25 | 丹麦技术大学 | 用于免疫细胞操作的抗原呈递支架 |
US11285196B2 (en) | 2017-03-13 | 2022-03-29 | Eslam Abbas Baseuny | Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof |
CN109306340B (zh) * | 2017-07-27 | 2023-06-06 | 上海细胞治疗研究院 | 一种高效扩增全t细胞的人工抗原递呈细胞及其用途 |
CN109337872B (zh) * | 2017-07-27 | 2023-06-23 | 上海细胞治疗研究院 | 高效扩增car-t细胞的人工抗原递呈细胞及其用途 |
EP3678701A4 (en) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF |
GB201801902D0 (en) * | 2018-02-06 | 2018-03-21 | Stichting Katholieke Univ | Immunomodulatory nanofilaments |
US20200390807A1 (en) * | 2018-02-20 | 2020-12-17 | University Of Florida Research Foundation, Incorporated | Composition and method for targeting natural killer cells in immunotherapy to overcome tumor suppression with manganese dioxide nanoparticles |
CN108588020B (zh) * | 2018-03-30 | 2021-09-14 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种含有硒元素的近红外ii区量子点的新应用 |
CN110464848B (zh) * | 2018-05-11 | 2022-07-05 | 中国医学科学院肿瘤医院 | 人工抗原递呈细胞及其制备方法与应用 |
JP2021527419A (ja) * | 2018-06-20 | 2021-10-14 | ダンマークス テクニスク ユニバーシテットDanmarks Tekniske Universitet | 免疫細胞操作用の安定化されたmhc分子を有するスカフォールド |
SG11202103296RA (en) * | 2018-10-18 | 2021-05-28 | Berkeley Lights Inc | Proto-antigen-presenting synthetic surfaces, activated t cells, and uses thereof |
CA3118757A1 (en) | 2018-11-08 | 2020-05-14 | Neximmune, Inc. | T cell compositions with improved phenotypic properties |
US20220331415A1 (en) * | 2019-09-18 | 2022-10-20 | The Regents Of The University Of California | Immunoactive microparticles and uses thereof |
MX2019015508A (es) | 2019-12-18 | 2021-06-21 | Univ Guadalajara | Nanopartículas para el tratamiento del cáncer. |
CN111172146B (zh) * | 2020-01-15 | 2023-09-12 | 苏州朴衡科技有限公司 | 纳米级人工抗原呈递细胞αCD3-Origami aAPC及其制备方法和应用 |
US20230126199A1 (en) | 2020-02-28 | 2023-04-27 | National University Corporation Kanazawa University | Immunoregulatory method, nucleic acid composition for immunoregulation and use thereof |
CN112517035A (zh) * | 2020-12-16 | 2021-03-19 | 兰州交通大学 | 一种金属原子掺杂空心MXene量子点的制备及应用 |
WO2023033124A1 (ja) * | 2021-09-01 | 2023-03-09 | 国立大学法人金沢大学 | 免疫制御法、免疫制御用核酸組成物およびその用途 |
WO2023060123A1 (en) * | 2021-10-05 | 2023-04-13 | The Johns Hopkins University | Mhc ii artificial antigen presenting cells harness the effector and helper functions of antigen-specific cd4+ t cells |
WO2023210661A1 (ja) * | 2022-04-25 | 2023-11-02 | 国立大学法人金沢大学 | CAR-T細胞活性化、造血幹細胞増殖、iPS細胞分化を制御する組成物およびその用途 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7973137B1 (en) | 1996-03-28 | 2011-07-05 | Johns Hopkins University | Cell compositions comprising molecular complexes that modify immune responses |
US6458354B1 (en) | 1996-03-28 | 2002-10-01 | The Johns Hopkins University | Molecular complexes which modify immune responses |
US6140113A (en) | 1996-03-28 | 2000-10-31 | The Johns Hopkins University | Polynucleotides encoding molecular complexes which modify immune responses |
JPH11507843A (ja) * | 1996-03-28 | 1999-07-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | タンパク質の可溶性二価および多価ヘテロ二量体類縁体 |
US6268411B1 (en) * | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
JP2004500095A (ja) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ, インコーポレイテッド | 細胞の同時の刺激および濃縮 |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7541184B2 (en) * | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
US7572631B2 (en) * | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
JP5068931B2 (ja) | 2002-07-12 | 2012-11-07 | ザ ジョンズ ホプキンス ユニバーシティー | 独自のクローン形質のリンパ球受容体に結合する試薬および方法 |
JP2006524991A (ja) * | 2003-05-08 | 2006-11-09 | エクサイト セラピーズ インコーポレーティッド | 抗原特異的t細胞の作製および単離の方法 |
WO2009094273A2 (en) * | 2008-01-15 | 2009-07-30 | Yale University | Compositions and methods for adoptive and active immunotherapy |
WO2010099205A1 (en) * | 2009-02-24 | 2010-09-02 | The Trustees Of The University Of Pennsylvania | Methods for treating progressive multifocal leukoencephalopathy (pml) |
US9115402B2 (en) | 2010-05-14 | 2015-08-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of identifying tumor specific neoantigens |
US10463750B2 (en) | 2013-02-15 | 2019-11-05 | The Johns Hopkins University | Antigen-Specific T cell redirectors |
CN105188755A (zh) * | 2013-02-26 | 2015-12-23 | 小利兰·斯坦福大学托管委员会 | 实现移植物移植耐受的联合器官和造血细胞 |
JP6632072B2 (ja) | 2013-03-14 | 2020-01-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | ナノスケール人工抗原提示細胞 |
KR20210032011A (ko) * | 2014-09-17 | 2021-03-23 | 더 존스 홉킨스 유니버시티 | 항원-특이적 t 세포 식별, 농축, 및/또는 증식을 위한 시약 및 방법 |
WO2020041968A1 (zh) * | 2018-08-28 | 2020-03-05 | 华为技术有限公司 | 表面波转换耦合装置和表面波通信系统 |
-
2014
- 2014-03-13 JP JP2016501989A patent/JP6632072B2/ja active Active
- 2014-03-13 CA CA2906514A patent/CA2906514C/en active Active
- 2014-03-13 US US14/775,855 patent/US10435668B2/en active Active
- 2014-03-13 SG SG10201707377XA patent/SG10201707377XA/en unknown
- 2014-03-13 CN CN201480027059.8A patent/CN105431523B/zh active Active
- 2014-03-13 AU AU2014244119A patent/AU2014244119B2/en active Active
- 2014-03-13 WO PCT/US2014/025889 patent/WO2014160132A1/en active Application Filing
- 2014-03-13 KR KR1020157028824A patent/KR102164405B1/ko active IP Right Grant
- 2014-03-13 EP EP14776027.6A patent/EP2970907B1/en active Active
- 2014-03-13 SG SG11201507506RA patent/SG11201507506RA/en unknown
- 2014-03-13 MX MX2015012920A patent/MX2015012920A/es active IP Right Grant
- 2014-03-13 ES ES14776027T patent/ES2782002T3/es active Active
-
2015
- 2015-09-16 IL IL241627A patent/IL241627B/he active IP Right Grant
-
2019
- 2019-08-23 US US16/548,953 patent/US11939595B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN105431523A (zh) | 2016-03-23 |
EP2970907A4 (en) | 2017-04-19 |
MX2015012920A (es) | 2016-06-02 |
US20160051698A1 (en) | 2016-02-25 |
EP2970907B1 (en) | 2020-01-01 |
US11939595B2 (en) | 2024-03-26 |
IL241627B (he) | 2020-05-31 |
US10435668B2 (en) | 2019-10-08 |
CA2906514A1 (en) | 2014-10-02 |
US20200095546A1 (en) | 2020-03-26 |
AU2014244119A1 (en) | 2015-10-08 |
CA2906514C (en) | 2021-07-27 |
KR102164405B1 (ko) | 2020-10-12 |
AU2014244119B2 (en) | 2019-08-15 |
WO2014160132A1 (en) | 2014-10-02 |
SG10201707377XA (en) | 2017-10-30 |
JP6632072B2 (ja) | 2020-01-15 |
JP2016520518A (ja) | 2016-07-14 |
CN105431523B (zh) | 2020-08-21 |
KR20150141962A (ko) | 2015-12-21 |
EP2970907A1 (en) | 2016-01-20 |
ES2782002T3 (es) | 2020-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201707377XA (en) | Nanoscale artificial antigen presenting cells | |
HK1232243A1 (zh) | 抗- 抗體及其用途 | |
IL266651B (he) | שתל | |
HK1217452A1 (zh) | 含有前列腺胺的眼内植入物 | |
AU350549S (en) | Breathalyzer | |
IL244016A0 (he) | שינוי תא פונדקאי עם אנדוסימביונטים מלאכותיים | |
HRP20190085T1 (hr) | Anti-cd52 protutijela | |
ZA201507795B (en) | Bacterial artificial chromosomes | |
EP3037112A4 (en) | PROSTHESIS | |
HK1219961A1 (zh) | 人抗α型干擾素抗體 | |
GB201319087D0 (en) | Artificial airway device | |
HUE057708T2 (hu) | Sejtek humán antitestek elõállítására | |
GB201310918D0 (en) | Prosthesis | |
PL3016977T3 (pl) | Ludzkie przeciwciała anty-IL-32 | |
GB201307275D0 (en) | Drivetrain Connections | |
EP2954047A4 (en) | PREPARATION OF DENT TYPE STRUCTURE USING STEM CELL | |
GB201421052D0 (en) | Artificial tissue | |
IL245048B (he) | פילטר מכני–ביולוגי | |
EP3001881A4 (en) | PHOTOVOLTAIC DEVICES AND METHODS OF MAKING THE SAME | |
CO6980135A1 (es) | Implante hibrido natural | |
IL230230A0 (he) | שתל | |
GB201310756D0 (en) | Implant | |
GB201320573D0 (en) | T Cell |